Concerns include observed associations between SGLT2 inhibitors and increased risk of normoglycemic ketoacidosis [3], urinary tract infections [4], electrolyte and acid–base disturbances [5], and early decline in glomerular filtration rate triggered by tubuloglomerular activation and decreased intraglomerular pressure [6]. This evidence concerns the gene SLC5A2 and urinary tract infection.